Grace focuses her practice on advising health plans, pharmacy benefit managers (PBMs), rebate aggregators, health care providers, and private equity firms on regulatory, transactional, and compliance matters. She serves as regulatory counsel to health care industry investors in transactions involving a range of health care targets and advises clients on structuring agreements that adapt to evolving regulatory frameworks and advance long-term business goals.
Drawing on her background as a registered nurse, Grace offers industry insight and a practical, commercially informed lens to contract negotiations, regulatory compliance matters, and complex transactions.
During law school, Grace interned with the US Department of Health and Human Services, serving both the Office of Counsel to the Inspector General and the Centers for Medicare & Medicaid Services, Office of the General Counsel. Prior to her legal career, Grace practiced as a registered nurse in a pediatric intensive care unit.
Grace earned her JD from the George Washington University Law School, where she was a member of the Business and Finance Law Review and a Health & FDA Law fellow. She also holds an MS in nursing from Columbia University and a BS in kinesiology and public health from Miami University.
viewpoints
A Pivotal Week for Pharmaceutical Policy: Trump Administration Advances Tariff and Drug Pricing Initiatives
October 7, 2025 | Blog | By Theresa Carnegie, Stephnie John, Hassan Shaikh, Attiya S. Khan, Grace Callander, Sneha Shenoy
The first week of October 2025 marked a significant shift in U.S. drug pricing policy as the Trump administration unveiled a series of sweeping actions to deliver on his promise to lower drug prices. From President Trump’s announcement of a 100% tariff on imported branded drugs to the Trump administration’s landmark pricing deal with Pfizer and the rollout of the TrumpRx.gov direct-to-consumer (DTC) platform, last week marked an escalation in the White House’s efforts to drive down prescription drug costs and bring pharmaceutical manufacturing back to U.S. soil. Below, we provide an overview of the Trump administration’s new policies and the stakeholder responses already reshaping the broader pharmaceutical landscape.
